FDA Approves Lipfendra (enlicitide) Oral PCSK9 Inhibitor to Reduce LDL-C in Adults with Hypercholesterolemia

Дата публикации: 16-07-2026 21:07:41

RAHWAY, N.J.--(BUSINESS WIRE) July 16, 2026 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide) tablets 20 mg as an adjunct to...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	What is the new FDA-approved pill designed to slash cholesterol levels?	0	5	17-07-2026
2	U.S. Food and Drug Administration Approves an Autoinjector Version of Lerochol (lerodalcibep-liga) and Updated Indication	0	10.87	17-08-2026
3	FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients	5	7	18-07-2026
4	Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development	0	17.54	24-07-2026
5	Tryngolza (olezarsen) Approved to Reduce Triglycerides and the Risk of Acute Pancreatitis in Patients with Severe Hypertriglyceridemia	0	8.04	24-06-2026
6	FDA Approves Leqembi Iqlik (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease	0	13.38	13-07-2026
7	FDA Approves Lytenava (bevacizumab-vikg) for the Treatment of Wet Age-Related Macular Degeneration	0	16.74	24-07-2026
8	U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir	0	14.72	29-04-2026
9	FDA Grants Accelerated Approval to Zenbexus (iberdomide) in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone for the Treatment of Multiple Myeloma	0	11.39	13-08-2026
10	Xeomin Approved For Expanded Indication in Pediatric Upper Limb Spasticity Patients with Cerebral Palsy Following FDA Label Update	0	10.02	26-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 15.63. Источник: www.drugs.com.